Board of Directors at their meeting held on today i.e. Tuesday 05th August, 2025 has inter alia considered and approved the various business as mentioned in attached outcome.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Limited's board, which met on August 5, 2025, approved the unaudited Q1 FY26 results (quarter ended June 30, 2025) along with the Board's Report and other AGM-related items. On a standalone basis, the company generated zero revenue from operations this quarter and reported a net loss of Rs. 39.75 lakhs versus a profit of Rs. 33.17 lakhs in the year-ago quarter, with EPS of -Rs. 0.32. On a consolidated basis, revenue from operations fell sharply to Rs. 268.76 lakhs from Rs. 619.44 lakhs (down ~57%), and the company slipped into a net loss of Rs. 349.19 lakhs compared to a loss of Rs. 55.65 lakhs in Q1 FY25, largely dragged by its pharma subsidiary Medgel Private Limited which posted a net loss of Rs. 309.44 lakhs. The board also fixed September 18, 2025 as the date for the 42nd AGM (via video conferencing) and approved the appointment of Joshi Sahay & Company as Secretarial Auditor for five years and the re-appointment of independent director Mr. Dharmendra Solanki for a second five-year term.
Shareholders should brace for weak near-term sentiment — the company has swung to losses on both standalone and consolidated bases, the pharma subsidiary is bleeding, and revenue has collapsed. However, the real estate division remains profitable and the board is taking routine housekeeping steps (auditor and director appointments), so there is no governance red flag from this filing.